Erasca dips on patient death
ERAS-0015 data look good, but the company is punished for a pneumonitis death.
Revolution’s big reveal approaches
The group’s first pivotal readout, in second-line pancreatic cancer, is coming.
RAS buzz lifts Erasca
But the company still has a lot to prove with ERAS-0015.
Revolution goes adjuvant
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
GenFleet broadens its RAS ambitions
And Treeline and HengRui also get in on the pan-RAS act.
Revolution could have a first-line pancreatic balancing act
Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
Revolution mortgages royalties for more cash
“We need all the capital we can get our hands on," the company states.
